Details
Stereochemistry | MIXED |
Molecular Formula | C22H32N2O6 |
Molecular Weight | 420.4993 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CNCCCCCCNCC(O)C1=CC(O)=C(O)C=C1)C2=CC=C(O)C(O)=C2
InChI
InChIKey=OXLZNBCNGJWPRV-UHFFFAOYSA-N
InChI=1S/C22H32N2O6/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16/h5-8,11-12,21-30H,1-4,9-10,13-14H2
Molecular Formula | C22H32N2O6 |
Molecular Weight | 420.4993 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/195789Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789
Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html
Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Palliative | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789 |
Primary | Unknown Approved UseUnknown |
||
Preventing | GYNIPRAL Approved UseGynipral prevents threatened abortion with premature labour. |
Doses
Dose | Population | Adverse events |
---|---|---|
1 mg 3 times / day multiple, oral Recommended Dose: 1 mg, 3 times / day Route: oral Route: multiple Dose: 1 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
Other AEs: Tachycardia, Palpitation... Other AEs: Tachycardia Sources: Palpitation Tremor muscle |
1 mg 4 times / day multiple, intravenous Recommended Dose: 1 mg, 4 times / day Route: intravenous Route: multiple Dose: 1 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Palpitations, Tremor... |
500 ug 6 times / day multiple, respiratory Recommended Dose: 500 ug, 6 times / day Route: respiratory Route: multiple Dose: 500 ug, 6 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Tachycardia, Palpitation... Other AEs: Tachycardia Sources: Palpitation Tremor muscle |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Palpitation | 1 mg 3 times / day multiple, oral Recommended Dose: 1 mg, 3 times / day Route: oral Route: multiple Dose: 1 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
|
Tachycardia | 1 mg 3 times / day multiple, oral Recommended Dose: 1 mg, 3 times / day Route: oral Route: multiple Dose: 1 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
|
Tremor muscle | 1 mg 3 times / day multiple, oral Recommended Dose: 1 mg, 3 times / day Route: oral Route: multiple Dose: 1 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
|
Palpitations | 11% | 1 mg 4 times / day multiple, intravenous Recommended Dose: 1 mg, 4 times / day Route: intravenous Route: multiple Dose: 1 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Tremor | 9% | 1 mg 4 times / day multiple, intravenous Recommended Dose: 1 mg, 4 times / day Route: intravenous Route: multiple Dose: 1 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Palpitation | 500 ug 6 times / day multiple, respiratory Recommended Dose: 500 ug, 6 times / day Route: respiratory Route: multiple Dose: 500 ug, 6 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
Tachycardia | 500 ug 6 times / day multiple, respiratory Recommended Dose: 500 ug, 6 times / day Route: respiratory Route: multiple Dose: 500 ug, 6 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
Tremor muscle | 500 ug 6 times / day multiple, respiratory Recommended Dose: 500 ug, 6 times / day Route: respiratory Route: multiple Dose: 500 ug, 6 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Tocolysis with hexoprenalin and salbutamol in a clinical comparison]. | 1983 Mar |
|
A comparison of the relative toxicities of beta-sympathomimetic tocolytic agents. | 1985 Oct |
|
Management of foetal asphyxia by intrauterine foetal resuscitation. | 2010 Sep |
|
Dependence of the lymphocyte proliferative response on the endogenous cortisol level and sensitivity to β-adrenergic regulation in vitro in the early period of penetrating eye injury. | 2010 Sep-Oct |
Sample Use Guides
Hexoprenaline can be given by metered aerosol in doses of 200 to 400μg, up to 5 times daily (in asthma), or as an infusion of 0,30 ug and 0,45 ug per minute or as 1-2 tablets q.i.d (0.5 mg per tablet) (maintenance dose in premature labour).
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:16:35 GMT 2025
by
admin
on
Mon Mar 31 19:16:35 GMT 2025
|
Record UNII |
G9L6B3W684
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03AC06
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
||
|
WHO-ATC |
R03CC05
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
||
|
WHO-VATC |
QR03CC05
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
||
|
WHO-VATC |
QR03AC06
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2650
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
100000083961
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
DTXSID7048322
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
HEXOPRENALINE
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL1589896
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
5307
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | RxNorm | ||
|
G9L6B3W684
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
DB08957
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
D006594
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
C170044
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
3215-70-1
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
3609
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
m6013
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB08041MIG
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY | |||
|
1372
Created by
admin on Mon Mar 31 19:16:35 GMT 2025 , Edited by admin on Mon Mar 31 19:16:35 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |